Equity Overview
Price & Market Data
Price: $0.923
Daily Change: -$0.0172 / 1.86%
Range: $0.91 - $0.97
Market Cap: $60,794,896
Volume: 63,299
Performance Metrics
1 Week: 3.69%
1 Month: -21.13%
3 Months: 3.10%
6 Months: -22.45%
1 Year: -35.92%
YTD: 0.30%
Company Details
Employees: 80
Sector: Health technology
Industry: Biotechnology
Country: Denmark
Details
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.